P08.04 Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer

• DOI: 10.1136/jitc-2022-itoc9.50
• Publication Date: 2022-09-22T00:34:43Z
• Authors: C Pan; Z Zhu; A Ma; H Zhang; T Lin; H Farrukh; Y Li; K Lam

<h3>Background</h3> Immune checkpoint inhibitors (ICIs) in general have shown poor efficacy bladder cancer (BCa). The purpose of this project is to determine whether photodynamic therapy (PDT) with BCa-specific porphyrin-based PLZ4-nanoparticles (PNP) potentiated ICI. <h3>Materials and Methods</h3> SV40 T/Ras double-transgenic mice bearing orthotopic BCa C57BL/6 carrying syngeneic models were used the conduct molecular correlative studies. <h3>Results</h3> PDT PNP generated reactive oxygen species, induced protein carbonylation, dendritic cell maturation. In cancer, median survival was 33.7 days control, compared 44.8 (p=0.0123), 52.6 (p=0.0054) over 75 (p=0.0001) anti-PD-1, combination groups, respectively. At Day when all other groups died, only one 7 group died. For direct anti-tumor activity, ani-PD-1, a 40.25% (p=0.0003), 80.72% (p&lt;0.0001) 93.03% reduction, abscopal anti-cancer immunity, tumor reduction 45.73% (p=0.0001), 54.92% 75.96% (p&lt;0.0001), also diminished spontaneous lung metastasis. Potential immunotherapy by multifactorial. <h3>Conclusions</h3> addition its potential for diagnosis therapy, can synergize treating locally advanced metastatic cancer. Clinical trials are warranted toxicity combination. <h3>Disclosure Information</h3> <b>C. Pan:</b> E. Ownership Interest (stock, stock options, patent or intellectual property); Significant; LP Therapeutics. <b>Z. Zhu:</b> None. <b>A. Ma:</b> <b>H. Zhang:</b> <b>T. Lin:</b> Farrukh:</b> <b>Y. Li:</b> <b>K. Lam:</b>